Patrick Ott is the Director of the Center for Cancer Vaccines and the Clinical Director of the Melanoma Center at Dana Farber Cancer Institute. His primary research interests are in melanoma and immunotherapy, specifically the development of innovative tumor vaccine approaches. Dr. Ott led several of the earliest clinical trials testing personalized neoantigen vaccines in patients with cancer. These studies are widely considered pioneering work for the therapeutic area of personalized neoantigen cancer vaccines and provided the rationale for randomized clinical trials in patients with melanoma and other cancers. As IND holder for a personalized multi-peptide vaccine targeting patient tumor-specific neoantigens (NeoVax) Dr. Ott oversees a portfolio of investigator-initiated phase 1 clinical trials testing these vaccines in patients with melanoma and other solid and hematological malignancies.